Heron Therapeutics (HRTX) stock price, revenue, and financials

Heron Therapeutics market cap is $1.3 b, and annual revenue was $88.64 m in FY 2020

$1.3 B

HRTX Mkt cap, 23-Sept-2021

$88.6 M

Heron Therapeutics Revenue FY, 2020
Heron Therapeutics Gross profit (FY, 2020)52.4 M
Heron Therapeutics Gross profit margin (FY, 2020), %59.2%
Heron Therapeutics Net income (FY, 2020)-227.3 M
Heron Therapeutics EBIT (FY, 2020)-228.2 M
Heron Therapeutics Cash, 31-Dec-2020105.1 M
Heron Therapeutics EV1.2 B
Get notified regarding key financial metrics and revenue changes at Heron TherapeuticsLearn more
Banner background

Heron Therapeutics Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

251.0k3.6m8.5m8.6m11.6m19.8m31.6m36.7m42.6m25.4m22.7m20.0m

Cost of goods sold

1.2m1.0m1.1m3.1m5.2m7.6m15.0m13.6m17.2m10.6m9.0m7.2m

Gross profit

2.4m7.5m7.5m8.4m12.2m16.6m23.1m25.4m14.8m13.7m12.8m

Gross profit Margin, %

67%88%88%73%62%53%63%60%58%60%64%

Sales and marketing expense

11.9m11.0m12.2m11.6m14.8m13.5m13.8m14.5m16.3m28.7m23.6m17.0m20.2m15.6m12.5m

R&D expense

1.3m2.9m3.3m3.1m3.6m6.8m10.5m5.9m11.8m14.4m14.7m14.5m16.2m14.2m16.1m27.3m30.2m33.4m28.6m28.8m39.6m30.2m30.4m43.0m41.4m34.7m36.9m44.0m49.2m

General and administrative expense

509.0k1.2m1.4m1.3m2.4m6.0m4.7m6.8m5.6m4.4m4.2m5.9m6.8m8.3m5.4m4.8m5.3m6.7m6.2m6.5m7.0m6.2m7.3m9.6m9.8m8.6m10.4m9.8m9.5m

Operating expense total

1.8m4.1m4.8m4.4m6.1m12.8m15.2m12.7m17.3m18.8m19.0m20.4m23.0m22.5m33.3m43.1m47.7m51.7m49.6m48.8m60.4m56.1m54.0m81.3m74.9m60.3m67.5m69.4m71.2m

EBIT

(1.5m)(4.1m)(4.8m)(4.4m)(6.1m)(12.8m)(15.2m)(12.7m)(17.3m)(18.8m)(19.0m)(20.4m)(23.0m)(22.5m)(33.3m)(43.1m)(47.7m)(49.3m)(42.1m)(41.3m)(52.0m)(38.9m)(41.8m)(64.7m)(51.8m)(34.9m)(52.7m)(55.7m)(58.4m)

EBIT margin, %

(614%)(1357%)(494%)(482%)(449%)(211%)(205%)(141%)(82%)(208%)(246%)(292%)

Interest expense

263.0k62.0k61.0k146.0k195.0k201.0k204.0k209.0k210.0k160.0k744.0k552.0k

Pre tax profit

(4.8m)

Net Income

(1.9m)(4.2m)(4.9m)(4.6m)(6.1m)(13.0m)(15.4m)(12.9m)(17.5m)(19.0m)(19.2m)(20.6m)(23.1m)(22.7m)(33.4m)(43.2m)(48.5m)(50.3m)(42.8m)(41.9m)(52.3m)(38.7m)(38.3m)(63.0m)(50.2m)(33.6m)(51.6m)(55.2m)(58.2m)

Heron Therapeutics Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

21.3m21.0m13.4m12.4m60.0m45.7m34.8m22.6m57.5m105.0m86.2m55.6m171.5m153.0m68.0m61.9m45.6m83.5m30.3m65.5m46.6m258.9m53.9m23.5m53.0m60.1m103.3m80.7m95.1m

Accounts Receivable

10.3m18.6m28.9m37.7m45.9m53.6m74.0m66.8m67.0m34.8m37.5m33.7m

Prepaid Expenses

499.0k301.0k306.0k557.0k355.0k427.0k360.0k763.0k2.3m518.0k3.0m945.0k1.9m2.0m5.1m3.2m3.1m3.4m3.7m4.6m5.5m6.6m10.2m11.5m8.7m16.7m12.4m13.1m16.4m

Inventories

2.7m3.3m2.0m4.6m4.8m5.2m19.4m27.2m31.4m31.4m29.3m24.2m34.8m41.4m42.7m

Current Assets

21.8m21.3m13.8m13.0m60.4m46.1m35.2m23.4m59.7m105.5m89.2m56.5m173.4m155.0m108.2m81.1m94.0m183.6m136.4m112.6m176.6m502.6m460.1m406.2m380.8m364.1m438.4m392.9m351.0m

PP&E

263.0k346.0k1.1m1.1m1.2m2.7m2.7m2.9m2.9m3.0m2.9m3.0m2.9m3.0m3.6m4.5m4.7m5.7m5.8m5.3m6.5m7.5m10.6m16.3m17.9m16.3m21.9m21.9m21.7m

Total Assets

22.1m21.8m15.0m14.2m61.8m49.0m38.1m26.4m62.8m108.6m92.3m59.6m176.5m158.2m111.8m85.7m98.8m189.6m142.4m118.2m183.4m510.6m470.9m435.8m411.7m393.0m478.9m432.7m390.0m

Accounts Payable

289.0k433.0k890.0k605.0k1.8m3.8m5.4m2.3m3.6m1.8m1.5m2.4m3.0m2.7m6.9m8.7m6.1m4.5m6.3m5.3m11.5m5.0m9.6m10.8m8.0m1.6m11.6m18.5m12.1m

Short-term debt

4.6m4.7m2.8m2.8m2.9m

Current Liabilities

3.2m2.5m3.4m3.1m4.2m7.6m9.6m5.5m7.4m10.8m11.3m11.6m16.6m16.5m19.2m27.9m30.9m37.4m48.3m53.1m91.2m78.7m64.1m92.3m95.1m96.7m96.8m92.7m97.6m

Long-term debt

11.7m11.3m10.8m16.7m16.0m15.3m

Total Debt

4.6m4.7m11.7m11.3m10.8m19.5m18.8m18.2m

Total Liabilities

3.2m2.6m3.4m80.9m87.4m73.3m78.1m104.0m106.3m107.5m113.5m108.7m112.9m

Common Stock

401.0k2.0m2.0m2.0m3.0m3.1m3.1m3.1m239.0k289.0k292.0k296.0k356.0k359.0k363.0k390.0k391.0k537.0k539.0k546.0k650.0k775.0k780.0k789.0k798.0k800.0k906.0k908.0k909.0k

Additional Paid-in Capital

151.2m173.2m174.8m178.8m230.3m234.9m237.4m242.6m311.6m373.0m375.3m383.5m518.4m522.9m538.6m547.0m555.5m738.0m747.6m760.5m925.7m1.3b1.3b1.4b1.4b1.4b1.6b1.6b1.6b

Retained Earnings

(151.8m)(156.0m)(165.2m)(169.7m)(175.8m)(196.5m)(212.0m)(224.8m)(256.4m)(275.4m)(294.6m)(335.8m)(358.9m)(381.6m)(446.3m)(489.5m)(538.0m)(636.3m)(679.1m)(721.0m)(834.1m)(872.8m)(911.2m)(1.0b)(1.1b)(1.1b)(1.2b)(1.3b)(1.3b)

Total Equity

18.9m19.2m11.6m11.1m57.5m41.4m28.5m20.9m55.4m97.8m81.0m48.0m159.9m141.7m92.7m57.8m17.9m102.2m69.1m40.1m92.2m431.9m406.8m331.8m305.4m285.4m365.5m324.1m277.1m

Financial Leverage

1.2 x1.1 x1.3 x1.3 x1.1 x1.2 x1.3 x1.3 x1.1 x1.1 x1.1 x1.2 x1.1 x1.1 x1.2 x1.5 x5.5 x1.9 x2.1 x3 x2 x1.2 x1.2 x1.3 x1.3 x1.4 x1.3 x1.3 x1.4 x

Heron Therapeutics Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(3.4m)(7.6m)(4.9m)(9.5m)(15.6m)(13.0m)(28.4m)(41.2m)(17.5m)(36.5m)(55.7m)(20.6m)(43.7m)(66.3m)(33.4m)(76.7m)(125.2m)(50.3m)(93.1m)(135.0m)(52.3m)(90.9m)(129.3m)(63.0m)(113.2m)(146.8m)(51.6m)(106.8m)(165.0m)

Depreciation and Amortization

94.0k137.0k51.0k94.0k147.0k70.0k149.0k237.0k114.0k239.0k389.0k152.0k323.0k498.0k238.0k489.0k793.0k329.0k741.0k1.1m381.0k711.0k1.1m467.0k959.0k1.5m621.0k1.4m2.1m

Accounts Receivable

(110.0k)(110.0k)(8.4m)(16.7m)(26.9m)4.2m(4.0m)(11.8m)(9.4m)(2.2m)(2.3m)5.1m2.4m6.2m

Inventories

(2.7m)(3.3m)(2.0m)699.0k539.0k171.0k(9.5m)(17.3m)(21.5m)7.6m9.8m14.9m(9.9m)(16.5m)(17.8m)

Accounts Payable

130.0k274.0k198.0k(74.0k)980.0k1.3m2.8m514.0k2.2m505.0k211.0k(166.0k)438.0k186.0k3.6m5.4m2.8m(2.3m)(499.0k)(1.5m)(7.3m)(13.8m)(9.1m)(6.1m)(8.9m)(15.2m)8.8m15.7m9.3m

Cash From Operating Activities

(2.6m)(5.2m)(4.1m)(8.1m)(10.9m)(8.0m)(18.8m)(31.1m)(15.7m)(28.2m)(47.4m)(19.7m)(35.5m)(55.4m)(32.4m)(59.5m)(95.6m)(50.6m)(82.6m)(123.2m)(61.7m)(122.4m)(158.3m)(49.0m)(72.1m)(97.6m)(32.9m)(90.2m)(132.3m)

Purchases of PP&E

(126.0k)(423.0k)(467.0k)(546.0k)(435.0k)(541.0k)(1.5m)(57.0k)(335.0k)(417.0k)(328.0k)(531.0k)(783.0k)(834.0k)(1.9m)(2.4m)(938.0k)(1.4m)(1.4m)(904.0k)(2.2m)(5.7m)(2.1m)(4.3m)(3.3m)(2.9m)(3.7m)(4.3m)

Cash From Investing Activities

(126.0k)(423.0k)(467.0k)(546.0k)(435.0k)(541.0k)(1.5m)(57.0k)(335.0k)(417.0k)(328.0k)(290.0k)(542.0k)22.7m41.2m10.1m(44.9m)(42.5m)28.1m(40.3m)(137.6m)(286.9m)34.1m75.9m104.6m63.8m96.2m152.2m

Long-term Borrowings

(25.0m)(25.0m)(25.0m)

Cash From Financing Activities

21.8m24.3m3.0m53.5m612.0k666.0k1.7m958.0k61.2m61.8m2.9m134.6m136.2m2.5m5.0m56.0m165.6m142.0m147.2m4.0m374.4m354.5m6.5m17.4m21.3m507.0k2.8m3.3m

Net Change in Cash

19.2m18.9m(4.5m)(5.5m)42.1m(7.8m)(18.7m)(30.9m)(14.8m)32.7m13.9m(17.1m)98.9m80.3m(7.2m)(13.2m)(29.5m)70.1m16.9m52.1m(98.0m)114.4m(90.6m)(8.4m)21.2m28.3m31.4m8.8m23.2m

Interest Paid

622.0k1.0m1.8m2.3m500.0k1.0m1.2m

Heron Therapeutics Ratios

USDQ2, 2011

Financial Leverage

1.2 x

Heron Therapeutics Employee Rating

3.513 votes
Culture & Values
2.6
Work/Life Balance
2.7
Senior Management
2.4
Salary & Benefits
3.9
Career Opportunities
2.5
Source